AIM
VIVO

Acrospire Investment Management’s Meridian Bioscience Inc VIVO Stock Holding History

Acrospire Investment Management’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-5,880
Closed -$93K – 1613
2017
Q2 		$93K Buy
+5,880
New +$84.7K 0.09% 293
2016
Q2 		– Sell
-2,100
Closed -$43K – 2349
2016
Q1 		$43K Buy
+2,100
New +$41.4K 0.03% 1087

Other funds holding VIVO

BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Acrospire Investment Management's VIVO Position: Q3 2017 in Review

Acrospire Investment Management sold out of Meridian Bioscience Inc (VIVO) in Q3 2017, closing a stake of 5,880 shares — an estimated $93K sold.

Acrospire Investment Management first reported a position in VIVO in Q1 2016 and held it in 2 quarters. The position peaked at $93K in Q2 2017. 172 funds tracked by Wall St. Rank hold VIVO as of Q3 2017.

  • Acrospire Investment Management reported no remaining Meridian Bioscience Inc position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 5,880 Meridian Bioscience Inc shares in Q3 2017, an estimated $93K.
  • Acrospire Investment Management first reported a position in Meridian Bioscience Inc in Q1 2016 and held it in 2 quarters.
  • Acrospire Investment Management's Meridian Bioscience Inc position peaked at $93K in Q2 2017.
  • 172 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.